Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Feline Hypertrophic Cardiomyopathy: ACVIM Staging, Diagnosis, and Evidence-Based Management
A clinician-facing evidence hub on feline HCM: ACVIM 2020 staging, echocardiographic diagnosis, clopidogrel-based thromboprophylaxis with the FAT CAT trial and its 2024 absolute-benefit re-analysis, acute FATE management, and emerging myosin-inhibitor and rapamycin therapies.
Read →Canine Dilated Cardiomyopathy: Hereditary DCM, Diet-Associated DCM, Preclinical Screening, and Evidence-Based Management
DCM affects up to 58% of Dobermans; annual Holter screening recommended from age 3. FDA grain-free/DCM investigation closed Dec 2022 without confirmed caus
Read →Meloxicam for Canine Osteoarthritis Pain: Efficacy, Safety, and 2025 Head-to-Head vs. Bedinvetmab
Meloxicam (COX-2 NSAID) equals bedinvetmab for canine OA efficacy in 2025 RCT (n=101), with more GI adverse events. Standard dose: 0.2 mg/kg loading the...
Read →Doxycycline for Tick-Borne Disease in Dogs and Cats: Ehrlichia, Anaplasma, RMSF, and Lyme
Doxycycline 10 mg/kg/day for 28 days treats all major tick-borne infections in dogs and cats; short courses risk recrudescence. Esophageal stricture ris...
Read →Phenobarbital for Canine Idiopathic Epilepsy: Prescribing Patterns, Pharmacometrics, and TDM
Phenobarbital remains the most-prescribed first-line ASD for canine idiopathic epilepsy (34.9% in US primary care). A 2025 population PK model enables precision dosing, while TDM to a 20-35 ug/mL target stays essential and is itself assay-dependent.
Read →Amoxicillin-Clavulanate (Clavamox) in Dogs and Cats: Indications, Stewardship, and Skin and UTI Evidence
Amoxicillin-clavulanate covers beta-lactamase-producing Staphylococcus and E. coli in skin/UTI. ISCAID 2019 prefers amoxicillin alone for uncomplicated ...
Read →Canine Parvovirus Enteritis in Dogs: Pathophysiology, Diagnosis, and Evidence-Based Management
An evidence-based clinical reference on canine parvovirus (CPV-2) enteritis: diagnosis, supportive-care standard of care, CPMA (Trutect) efficacy and dosing, outpatient protocols, and post-prophylaxis vaccine timing.
Read →Prednisolone and Prednisone in Dogs and Cats: Pharmacology, Dosing, and Adverse Effect Management
Prednisolone is the preferred oral glucocorticoid in cats (~100% bioavailability vs ~21% for prednisone), while dogs treat the two as equivalent. A clinician-facing evidence summary of dosing, tapering, adverse effects, and steroid-sparing agents across dogs and cats.
Read →Methimazole and Carbimazole for Feline Hyperthyroidism: Pharmacology, Dosing, and Adverse Effect Management
Methimazole 1.25-2.5 mg PO BID is the standard medical therapy for feline hyperthyroidism, controlling but not curing disease. This hub consolidates dosing, adverse-effect management, carbimazole and transdermal options, and how medical management compares with radioiodine, iodine-restricted diet, and surgery — including the concurrent-CKD reversibility trial.
Read →Velagliflozin (Senvelgo) for Feline Diabetes Mellitus: SGLT2 Inhibition, Efficacy and Safety
Velagliflozin (Senvelgo) is a once-daily oral SGLT2 inhibitor for the insulin-naive diabetic cat: the SENSATION trial (n=252) cut median blood glucose from 436 to 125 mg/dL by day 180. This hub covers efficacy, the euglycemic DKA hazard, mandatory BHB monitoring, patient selection, and how it compares with bexagliflozin and insulin.
Read →Robenacoxib for Feline Musculoskeletal Pain: COX-2 Selectivity, DJD Evidence, Safety, and the ISFM/AAFP Framework
The evergreen clinical hub on robenacoxib (Onsior) for feline musculoskeletal and DJD pain: COX-2 tissue selectivity and PK, the Adrian 2021 pilot RCT (49% disability reduction, NNT 3.8), King 2021 pooled chronic safety with a CKD subgroup, grapiprant comparator and NSAID-timing data, and the 2024 ISFM/AAFP monitoring framework.
Read →Pimobendan for Canine Myxomatous Mitral Valve Disease (MMVD): Evidence, Mechanism, and Use
Pimobendan's dual calcium-sensitizer and PDE3-inhibitor mechanism, the EPIC and QUEST pivotal trials, 2019 ACVIM staging, PROTECT DCM data, and the 2024-2026 reverse-remodeling evidence that says document baseline echo before you dose a Stage B2 dog.
Read →